Belite Bio, Inc reports results for the quarter ended June 30 - Earnings Summary

Belite Bio

13/08/2026 14:30

Belite Bio, Inc BLTE.OQ reported a quarterly adjusted loss of 70 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -50 cents.  The mean expectation of eight analysts for the quarter was for a loss of 79 cents per share. Wall Street expected results to range from -99 cents to -54 cents per share.
Reported revenue was zero​; analysts expected zero. 
Belite Bio, Inc's reported EPS for the quarter was a loss of 70 cents​.
The company reported a quarterly loss of $28.41 million.
Belite Bio, Inc shares had risen by 16.2% this quarter and gained 11.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 17.5% in the last three months.​ 
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." 
Wall Street's median 12-month price target for Belite Bio, Inc is $207.50, about 13.8% above its last closing price of $178.94
This summary was machine generated from LSEG data August 13 at 01:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.79
-0.70
Beat
Mar. 31 2026 
-0.64
-0.68
Missed
Dec. 31 2025 
-0.55
-0.70
Missed
Sep. 30 2025 
-0.49
-0.65
Missed